[The electroretinogram and visual evoked potentials in patients with Parkinson's disease]. 1990

J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
Servicio de NeurologĂ­a, Hospital La Fe, Valencia.

Whether Parkinson's disease patients have been shown to have abnormal visual evoked cortical potentials (VEPs) to flash and pattern stimulation or not, is a matter widely discussed. Actually it is said that this variability may be due to the stimulus method used and how the patients were selected. The retina is rich in dopamine and together with previous animal and human studies, this suggests that the abnormal VEPs in Parkinson's disease patients may be due to a biochemical and electrophysiological disorder in the retina. This hypothesis has been examined by studying the flash VEPs, pattern VEPs and with light electroretinogram in 29 Parkinson's disease patients and matched control subjects. We have found: a) Slower FVEPs and PEVPs latencies in Parkinson disease patients. Flash VEPS were more frequently abnormal than pattern VEPs. We have only found a significant relationship between slow flash VEPs and the patient age. b) Electroretinograms waves (a) and (b) amplitudes were smaller in Parkinson disease patients than in control subjects. b/a coefficient abnormal values must be due basically to wave (a) alterations. These values are statistically significant with respect to the number of years of L-Dopa in the evaluative stage and the evolutive stage of the illness. For all these reasons, we can deduce that an anomaly exists in the dopaminergic pathway in the retina, localized in the plexiform layer and neurophysiologically detectable by a study of the wave variations of the ERG and of the b/a coefficient.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004596 Electroretinography Recording of electric potentials in the retina after stimulation by light. Electroretinographies
D005074 Evoked Potentials, Visual The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways. Visual Evoked Response,Evoked Potential, Visual,Evoked Response, Visual,Evoked Responses, Visual,Potential, Visual Evoked,Potentials, Visual Evoked,Response, Visual Evoked,Responses, Visual Evoked,Visual Evoked Potential,Visual Evoked Potentials,Visual Evoked Responses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
May 1971, Nordisk medicin,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
December 1978, Brain : a journal of neurology,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
January 1980, Revue d'electroencephalographie et de neurophysiologie clinique,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
September 1996, Electroencephalography and clinical neurophysiology,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
June 1992, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
October 2001, Clinical neurology and neurosurgery,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
January 2013, PloS one,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
January 1996, Journal of neural transmission (Vienna, Austria : 1996),
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
January 1998, Documenta ophthalmologica. Advances in ophthalmology,
J A Burguera, and C Vilela, and A Traba, and Y Ameave, and M Vallet
January 1996, Dementia (Basel, Switzerland),
Copied contents to your clipboard!